RxDoctor Payments Data

Mary Rockers Tyni, NP

Adult Medicine · Durham, NCNPI 1295409035

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 32.8% of the total.

$545in general payments, 2019–2025

Across 30 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$179
  • IBSA Pharma Inc.$77
  • AbbVie$69
  • Exact Sciences$41
  • Takeda Pharmaceuticals U.S.A., Inc.$41
  • Boehringer Ingelheim$30
  • plus $109 from 5 others

What the payments were for

  • Food & beverage$545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$545 in reported general payments places this provider in the 75th percentile of 25 adult medicine providers in North Carolina.

See all adult medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$42,634
Medicare patients
177
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$41,341
JardianceEmpagliflozin32$31,795
TrulicityDulaglutide29$30,593
OzempicSemaglutide16$27,238
RybelsusSemaglutide12$21,365
MounjaroTirzepatide16$18,944
SymbicortBudesonide/Formoterol Fumarate12$3,944
Albuterol Sulfate HfaAlbuterol Sulfate59$2,097
Pregabalin28$1,352
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,264
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen30$1,133
Atorvastatin Calcium136$1,113
Omeprazole56$1,065
EndocetOxycodone Hcl/Acetaminophen15$817
Fluticasone Propionate37$737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$179$48,60428 claims
Boehringer IngelheimJardiance$30$31,79532 claims
AstraZenecaSymbicort$29$3,94412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 25 adult medicine providers in North Carolina.

Other adult medicine in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →